Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from MedCap AB ( (SE:MCAP) ).
MedCap AB reported strong growth for the fourth quarter of 2025, with net sales up 25% to SEK 591.0 million and EBITA rising 73% to SEK 122.1 million, lifting the EBITA margin to 20.7%. On an adjusted basis, EBITA grew 68% and the margin improved to 19.1%, while profit after tax reached SEK 65.0 million and earnings per share increased to SEK 4.3, supported by robust operating cash flow of SEK 151.5 million. For the full year 2025, net sales climbed 17% to SEK 2,108.0 million and EBITA increased 18% to SEK 388.6 million, with adjusted EBITA up 26% and the adjusted margin strengthening to 18.3%, underscoring continued margin expansion and solid profitability that reinforce MedCap’s financial position and operational momentum within its healthcare niche.
The most recent analyst rating on (SE:MCAP) stock is a Hold with a SEK541.00 price target. To see the full list of analyst forecasts on MedCap AB stock, see the SE:MCAP Stock Forecast page.
More about MedCap AB
MedCap AB (publ.) is a Swedish investment company focused on acquiring and developing profitable, niche healthcare and medical technology businesses, with operations concentrated in specialized segments of the Nordic healthcare market.
Average Trading Volume: 13,866
Technical Sentiment Signal: Hold
Current Market Cap: SEK7.43B
For detailed information about MCAP stock, go to TipRanks’ Stock Analysis page.